Citigroup Maintains Buy on Royalty Pharma, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Andrew Baum maintains a Buy rating on Royalty Pharma (NASDAQ:RPRX) but lowers the price target from $60 to $40.

October 25, 2024 | 6:27 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Citigroup's analyst Andrew Baum maintains a Buy rating on Royalty Pharma but lowers the price target from $60 to $40, indicating a more cautious outlook.
The maintained Buy rating suggests continued confidence in Royalty Pharma's prospects, but the lowered price target reflects a more cautious outlook, possibly due to market conditions or company-specific factors. This mixed signal may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100